FDA Extends Review of Ascendis Pharma’s Dwarfism Treatment

The U.S. Food and Drug Administration (FDA) has officially extended the review period for the New Drug Application (NDA) concerning Ascendis Pharma’s treatment for children with achondroplasia, known as TransCon CNP (navepegritide). The new action date is now set for February 28, 2026, extending the review by three months.

This decision follows a request from Ascendis Pharma, which is based in Denmark, as the company continues to work on providing this potentially life-changing therapy. Achondroplasia is the most common form of dwarfism, affecting an estimated 1 in 15,000 births. The condition results from a genetic mutation that hinders bone growth, leading to short stature and various skeletal complications.

The FDA’s extension allows the agency additional time to evaluate the available data regarding the efficacy and safety of TransCon CNP. The treatment aims to address the underlying causes of achondroplasia rather than merely alleviating symptoms. This innovative approach has garnered attention from both the medical community and potential patients.

Ascendis Pharma is committed to advancing the development of this therapy and remains in communication with the FDA throughout the review process. The company has expressed confidence in the data submitted and the potential of TransCon CNP to improve the lives of children living with achondroplasia.

As the new action date approaches, stakeholders will be closely monitoring updates from the FDA. The decision highlights the ongoing efforts to ensure that promising medical treatments undergo thorough scrutiny before reaching the market, ensuring their safety and efficacy for those in need.